Observes adults with triple-negative breast cancer during standard treatment
Follows patients with triple-negative breast cancer through standard treatment, including quality of life.
Plain-language title generated from the registry record
Registry title: TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
Key facts
- Where
- Amsterdam, Breda, Deventer, Enschede, Groningen, Maastricht, Nijmegen, and Rotterdam, NetherlandsSee the 9 sites
Where in Netherlands
- Amsterdam University Medical CenterAmsterdam, NetherlandsNot yet recruiting
- The Netherlands Cancer InstituteAmsterdam, NetherlandsTaking people
- AmphiaBreda, NetherlandsTaking people
- Deventer ZiekenhuisDeventer, NetherlandsNot yet recruiting
- Medical Spectrum TwenteEnschede, NetherlandsTaking people
- UMCGGroningen, NetherlandsTaking people
- Maastricht University Medical CenterMaastricht, NetherlandsTaking people
- CWZNijmegen, NetherlandsNot yet recruiting
- ErasmusMCRotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Netherlands Cancer Institute
- Trial code
- NCT06931769
- Record updated
- 7 October 2026
- Original description
This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application.Read full original descriptionShow less
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application.
For all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.
Inclusion: Patients aged 18 years or older; Histologically confirmed adenocarcinoma of the breast; Assumed clinical or pathological stage III (TNM) breast cancer; Breast tumor must be:; HER2-negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH); Hormone receptor negative i.e. an estrogen receptor (ER) of <10% and progesterone receptor (PR) of <10%.; or in case of a histological grade III tumor an ER of <50% and a PR of <50%; Patients are planned to receive the complete standard of care in the Netherlands; neo-adjuvant chemotherapy according to local practise; Participating patients have to be able to use a mobile phone, tablet, laptop and/or computer and understand the Dutch language.
Exclusion: Evidence of distant metastases. Staging examinations should have been performed according to Dutch national guidelines; Patients who are only treated systemically in the adjuvant setting; Participation in another clinical study with an treatment intervention during the course of this study.